Related Experiment Videos
Investigation of the bleeding patterns of postmenopausal women treated with Estrapak-50
F al-Azzawi1, J Hawley, A Parsons
1Department of Obstetrics and Gynaecology, Leicester University School of Medicine, Royal Infirmary, UK.
Insights
Hormone replacement therapy with Estrapak-50 showed acceptable progestogen-associated bleeding (PAB) and breakthrough bleeding (BTB) patterns in most patients. Bleeding was generally light and limited to one cycle, indicating adequate endometrial protection.
Area of Science:
- Reproductive Endocrinology
- Pharmacology
Background:
- Hormone replacement therapy (HRT) is used to manage menopausal symptoms.
- Understanding bleeding patterns associated with HRT is crucial for patient adherence and safety.
- Estrapak-50 is a specific HRT formulation requiring evaluation of its bleeding profile.
Purpose of the Study:
- To analyze progestogen-associated bleeding (PAB) and breakthrough bleeding (BTB) patterns in patients using Estrapak-50.
- To assess the acceptability and implications of observed bleeding patterns in two similar clinical trials.
Main Methods:
- Diary card analysis of bleeding events in patients undergoing Estrapak-50 HRT.
- Evaluation of PAB and BTB characteristics, including timing, duration, and severity.
- Comparison of bleeding patterns between two similar study cohorts (Study A and Study B).
Main Results:
- Approximately 70-90% of patients experienced PAB by day 11 after 6 months of treatment.
- A significant proportion (27-49%) experienced bleeding before day 8, often affecting only one cycle.
- Bleeding duration varied (median 7 days), and patterns in the second cycle predicted subsequent bleeding; most bleeding was light, and BTB did not suggest pathology.
Conclusions:
- Bleeding patterns associated with Estrapak-50 HRT were generally acceptable to patients.
- The observed bleeding profiles suggest adequate progestogenic protection of the endometrium.
- Further interpretation of bleeding patterns aligns with current literature on HRT efficacy and safety.
Abstract:
Diary cards of patients in two similar trials of Estrapak-50 hormone replacement therapy were analysed with regard to the characteristics of progestogen-associated bleeding (PAB) and breakthrough bleeding (BTB). Forty out of 52 patients in Study A and 74 out of 92 patients in Study B had diaries suitable for analysis. One patient in Study A and two patients in Study B who withdrew from treatment did so because of unacceptable bleeding problems. Similar results were obtained from both trials. After 6 months of treatment approximately 90% of patients in study A and approximately 70% of patients in study B had PAB on or before day 11. Twenty-seven percent and 49% in studies A and B, respectively, bled prior to day 8, which in the majority of instances affected one treatment cycle. Duration of PAB varied from 1 to 14 days (median 7 days) and the pattern of bleeding in the second cycle was predictive of bleeding in subsequent cycles. Although over 1/3 of women reported some heavy bleeding days, this usually only affected one treatment cycle, and the majority of bleeding was only spotting or light flow. BTB patterns did not raise suspicions of endometrial pathology. Bleeding patterns were both acceptable to patients and, in as much as the current literature indicates that bleeding patterns can be interpreted, were consistent with adequate progestogenic protection of the endometrium.